Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Zi Chen et al.|Clinical Cancer Research|2023Cited by 38
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Sudipto Mukherjee et al.|JAMA Oncology|2024Cited by 26
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Clinical Cancer Research|2023Cited by 24
Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global StudyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Blood|2022Cited by 16